Bone Biologics Corp
Research Bone Biologics Corp (BBLG) on Bullrun: market cap USD 845.46K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBBLG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 845.46K
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 773.70K
- Free cash flow-USD 518.44K
Valuation Snapshot
latest market cap is USD 845.46K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 3.11M | -USD 2.69M | n/a | -2.65 | USD 5.33M | n/a | USD 5.38M |
| FY2024 | USD 0 | -USD 4.11M | -USD 4.12M | n/a | -28.96 | USD 3.33M | n/a | USD 3.48M |
| FY2023 | USD 0 | -USD 8.95M | -USD 9.56M | n/a | -34.01 | USD 3.03M | n/a | USD 2.91M |
| FY2022 | USD 0 | -USD 1.48M | -USD 3.57M | n/a | -31.15 | USD 7.54M | n/a | USD 5.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 845.46K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.78M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.41M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.21M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 36.50M | n/a | n/a | n/a |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bone Biologics Corp's market cap?
Bone Biologics Corp's market capitalization is USD 845.46K.
What does Bone Biologics Corp do?
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine.